{
    "clinical_study": {
        "@rank": "95725", 
        "arm_group": [
            {
                "arm_group_label": "drug eluting balloon catheter", 
                "arm_group_type": "Experimental", 
                "description": "use drug eluting balloon catheter to inflate the stenosis or occlusion in superficial femoral artery(SFA) and/or popliteal artery"
            }, 
            {
                "arm_group_label": "common balloon catheter(uncoated drug)", 
                "arm_group_type": "Active Comparator", 
                "description": "use common balloon catheter to inflate stenosis or occlusion in SFA and/or popliteal artery"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether DEB is more effective than common PTA\n      balloon in long-term vessel patency and inhibiting restenosis."
        }, 
        "brief_title": "Effectiveness and Safety Study of Drug Eluting Balloon(DEB) in Percutaneous Transluminal Angioplasty(PTA) Procedure", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Peripheral Artery Disease", 
        "condition_browse": {
            "mesh_term": "Peripheral Arterial Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age between 18 and 80 years\n\n          -  Patients with peripheral artery disease (PAD), with Rutherford classification between\n             2 and 5\n\n          -  an occlusion or a minimum grade of stenosisPrimary over 70% in the superficial\n             femoral artery an /or the popliteal artery\n\n          -  Total length of treat lesion(s)is less or equal to 40cm\n\n          -  signed Patient informed consent form\n\n        Exclusion Criteria:\n\n          -  plasma Cr level greater than 150 umol/L in patients\n\n          -  patients with acute thrombosis requiring lysis or thrombectomy\n\n          -  patient with a lysis or an lower limb intervention as a therapy within the last 6\n             weeks\n\n          -  patient requiring intervention in both  lower limbs at the same time\n\n          -  target lesion can't be cross by the guide wire\n\n          -  distal outflow through less than one lower leg vessel\n\n          -  known hypersensitivity to aspirin, heparin, clopidogrel,paclitaxel, contrast medium,\n             etc.\n\n          -  patients participating in another clinical trials with interfere with this trial in\n             the past 3 months\n\n          -  pregnancy and lactating woman\n\n          -  untreatable bleeding diatheses\n\n          -  other diseases, such as cancer, liver disease, or cardiac insufficiency, which may\n             lead to protocol violations or markedly shorten a patients's life expectancy(less\n             than 2 years)\n\n          -  patients unable or unwilling to participate this trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01850056", 
            "org_study_id": "acotec-02"
        }, 
        "intervention": [
            {
                "arm_group_label": "drug eluting balloon catheter", 
                "intervention_name": "drug eluting balloon catheter (trade name: Orchid)", 
                "intervention_type": "Device", 
                "other_name": "drug eluting dilation catheter"
            }, 
            {
                "arm_group_label": "common balloon catheter(uncoated drug)", 
                "intervention_name": "common percutaneous transluminal angioplasty balloon catheter (trade name: Admiral)", 
                "intervention_type": "Device", 
                "other_name": "common PTA catheter"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "drug eluting balloon catheter", 
        "lastchanged_date": "May 5, 2014", 
        "location": {
            "contact": {
                "email": "pla301dml@vip.sina.com", 
                "last_name": "Wei Guo, Dr"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "zip": "100853"
                }, 
                "name": "Wei Guo"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Prospective, Multi-center and Randomized Controlled Clinical Study to Verify Effectiveness and Safety of Drug-eluting Balloon in PTA Procedure", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "measure difference of the MLD(minimal lumen diameter) at 0 time and 6 months", 
            "measure": "Late Lumen Loss", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01850056"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "measure minimal lumen diameter (MLD) of target lesion", 
                "measure": "Minimal lumen diameter (MLD)", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "stenosis over 50% is defined as restenosis", 
                "measure": "Restenosis rate of target vessel", 
                "safety_issue": "No", 
                "time_frame": "6 months, 12 months, 18 months, 24months"
            }, 
            {
                "description": "target lesion revascularization is defined as any reintervention of artery bypass graft surgery involving the target lesion", 
                "measure": "target lesion revascularization", 
                "safety_issue": "No", 
                "time_frame": "6 months, 12 months, 18 months, 24 months"
            }, 
            {
                "description": "based the following definition of Rutherford stage, evaluate the stage of patient. Then compare the stage of patient just after procedure and 6 months after treatment\nStage    clinical symptom\n0         asymptomatic\nmild claudication\nmoderate claudication\nsevere claudication\nischemic rest pain\nminor tissue loss\nulceration or gangrene", 
                "measure": "change in Rutherford stage", 
                "safety_issue": "No", 
                "time_frame": "6 months, 12 months, 18 months, 24 months"
            }, 
            {
                "description": "change in ankle brachial index(ABI) compared to pretreatment", 
                "measure": "change in ankle brachial index(ABI)", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "major amputation at the index limb(major amputation is defined as an amputation above the foot)", 
                "measure": "major amputation", 
                "safety_issue": "No", 
                "time_frame": "6 months, 12 months, 18 months, 24 months"
            }, 
            {
                "description": "death of any cause", 
                "measure": "Death", 
                "safety_issue": "No", 
                "time_frame": "12 months, 18 months, 24 months"
            }
        ], 
        "source": "Acotec Scientific Co., Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Acotec Scientific Co., Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}